Form 4: Aura Biosciences CEO Elisabet de los Pinos Reports Stock and Option Transactions

Elisabet de los Pinos, CEO of Aura Biosciences, reports acquisition of restricted stock units and stock options, along with a correction to a previous filing.

Summary

• Elisabet de los Pinos, the President and CEO of Aura Biosciences, filed a Form 4 detailing changes in beneficial ownership.
• On February 3, 2025, she acquired 194,320 shares of common stock through a restricted stock unit (RSU) award under the company's 2021 Stock Option and Incentive Plan.
• These RSUs vest in four equal annual installments starting February 15, 2026, contingent on continued service.
• She also acquired options to buy 255,680 shares of common stock at an exercise price of $7.68, vesting 25% on February 3, 2026, and the remainder pro-rata over 36 months, also contingent on continued service.
• The filing includes a correction to a previous Form 4 filed on November 7, 2023, which incorrectly reported the number of shares beneficially owned directly and indirectly.
• After the reported transactions, de los Pinos directly owns 502,661 shares and indirectly owns 127,763 shares through the Elisabet de los Pinos Revocable Trust.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The filing reflects standard executive compensation practices and includes a correction of a previous error, indicating attention to detail. The acquisition of equity by the CEO is generally a positive signal.

Positives

• The acquisition of RSUs and stock options aligns the CEO's interests with those of the shareholders, incentivizing her to improve company performance.
• The vesting schedules for both the RSUs and stock options encourage long-term commitment from the CEO.

Future Outlook

The document does not contain specific forward-looking statements beyond the vesting schedules of the RSUs and stock options.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The acquisition of equity by the CEO is generally viewed positively as it aligns management's interests with shareholders'.

Comparison to Industry Standards

• Stock option and RSU grants are a common form of executive compensation in the biotechnology industry, used to attract and retain talent.
• Vesting schedules are typically structured to incentivize long-term performance and commitment, often over a 3-4 year period, which aligns with the vesting schedule reported in this document.
• Comparable companies such as Iveric Bio (now part of Astellas) and Apellis Pharmaceuticals also utilize similar equity-based compensation plans for their executives.

Stakeholder Impact

• The acquisition of equity by the CEO can positively impact shareholders by aligning management's interests with theirs.
• Employees may view the CEO's equity stake as a sign of confidence in the company's future.

Key Dates

Keywords

Aura Biosciences, Elisabet de los Pinos, Form 4, Beneficial Ownership, RSU, Stock Options, Vesting, Correction